1. Home
  2. Directory
  3. Oregon
  4. Portland
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1164537981

DR. RYAN GORGER OD
Prescription History 1164537981
Optometrist in Portland, OR

NPI Status: Active since August 20, 2006

Contact Information

800 SW 13TH AVE
PORTLAND, OR
ZIP 97205
Phone: (503) 221-0161

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. RYAN GORGER OD, an active Optometrist specialist practicing in Portland, OR. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 234 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 154 claims alone.

Medication Index

D
L
N
T
No matching medications currently found on file.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 16
30-Day Fills 36.2
Days Supply 1,086
OR State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills171.3
Peer Average Days Supply5,117
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 80.2% less volume than the regional standard for practitioners inside OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $732.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.80

State Avg Cost Per Claim

$30.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 154
30-Day Fills 320.0
Days Supply 9,303
OR State Average Benchmarks
Peer Average Claims146.0
Peer Average 30-Day Fills255.9
Peer Average Days Supply7,273
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,291.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.36

State Avg Cost Per Claim

$22.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.5
Days Supply 298
OR State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills38.6
Peer Average Days Supply556
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $520.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.80

State Avg Cost Per Claim

$15.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 33
30-Day Fills 64.2
Days Supply 1,926
OR State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills24.6
Peer Average Days Supply736
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 94.1% higher than the standard regional baseline profile for OR. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $632.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.18

State Avg Cost Per Claim

$385.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. RYAN GORGER OD provides transparency into local medical care patterns within Portland, OR.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.